Du är här


InvestmentPitch: Stonegate Securities Initiates Coverage on OxySure Systems (OTCQB:OXYS) - Video Research Alert on InvestmentPitch.com

Vancouver, BC, April 23, 2014 -. Dallas-based Stonegate Securities has
initiated coverage on OxySure Systems (OTCQB:OXYS). OxySure has pioneered a
safe and easy to use solution to produce medically pure oxygen from inert
powders, eliminating the need for a pressurized gas tank.

InvestmentPitch.com has produced a "video research alert" about OxySure based
on this report. If this link is not enabled, please
visitwww.InvestmentPitch.comand enter "OxySure" in the search box.

The company's Model 615 has FDA 510k clearance for over the counter sale,
giving the company a clear advantage over oxygen systems reliant on
pressurized oxygen tanks, which require a prescription. Users simply plug in
the mask, turn the knob, and place the mask over the nose and mouth.

The Model 615 has quickly gained adoption amongst various school districts,
military units, and institutional buyers, where early administration of
medical oxygen in respiratory emergencies can often save a trip to the

Earlier this month, the Model 615 received CE Mark approval, a critical step
toward launching this unique product into the 30 countries belonging to the
European Economic Area.

The Stonegate report points out several advantages of the Model 615 over tank
based solutions in terms of safety and applicability. For example, tanks can
create harmful explosions when submersed in fires. Furthermore, oxygen tanks
lose their pressure over time due to leaks in the casing.

Analyst Dan Tang stated, "The future bodes well for the Company as more
distributors push Model 615 in
their respective channels and the Company makes progress in penetrating new
vertical markets

On April 16th, OxySure reported fourth quarter and full year financial results
for the period ending December 31, 2013. Revenues for the year were $1.8
million, up 566%, led by a 787% increase in revenues in the United States.
Net loss per share for the year was cut in half from $0.06 to $0.03.

Unit cartridge reorder rates continued to increase as the installed base of
Model 615 increased, giving the company recurring sales.

Julian T. Ross, Chairman and CEO stated, "We finished the year strong, and our
fundamentals continue to improve. We are
pleased to have delivered on a number of our sales and business goals for the
year, including growing our international distribution footprint, building
our brand, diversifying our revenue streams and strengthening our balance
sheet. I'm also very excited about the way our products are continuing to
save or improve people's lives

Although not giving a target price at this time, analyst Dan Tang stated, "On
multiple base comparison among publicly listed peers, comparable companies
trade at 7.9x on EV/Sales basis for 2014E whereas OXYS is trading at 4.7x

The company currently trades at $0.71, and with 24.2 million shares
outstanding, the company is capitalized at $17.2 million.

For more information about OxySure, please visit the company's

Investor relations is handled by Stonegate Securities, which can be reached at
214-987-4121 or by email atinvestors@oxysure.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution
for creating and hosting financial video content, and distributing it across
multiple platforms to investors and financial professionals, specializes in
producing corporate interviews and three minute videos based on news releases
and research reports. Please visit InvestmentPitch.com and browse our
extensive library of investment videos.

Barry Morgan, CFO


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InvestmentPitch via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.